Firdapse Falls Short in Phase 3 Trial in MuSK-MG Patients, Top-line Results Show

Firdapse (amifampridine phosphate), an investigational treatment for MuSK-antibody positive myasthenia gravis (MuSK-MG), failed to meet its primary or secondary goals, according to top-line results from a Phase 3 clinical trial.  The randomized trial (NCT03304054…

Catalyst Enrolls First MuSK MG Patient in Phase 3 Trial Evaluating Firdapse

Catalyst Pharmaceuticals recently enrolled the first patient into a Phase 3 clinical trial designed to evaluate the efficacy and safety of Firdapse (amifampridine phosphate) in patients with MuSK antibody-positive myasthenia gravis (MuSK MG). Firdapse is a neuronal potassium channel blocker that works to improve nerve impulses…

Catalyst Readies Phase 3 Study of Firdapse in Patients with MuSK-MG

Catalyst Pharmaceuticals announced that it will soon begin a Phase 3 clinical trial to assess Firdapse (amifampridine phosphate) in people with myasthenia gravis who are positive for the MuSK antibody. In meetings, the company and the U.S. Food and Drug Administration (FDA) arrived at an agreement regarding the size, scope and objectives of…